Summary A total of 98 breast aspirates from patients with breast cancer have been fixed and stained for oestrogen receptors using the Abbott ERICA kit. In a preliminary series of 41 aspirates, cytochemical staining index (% cells staining x mean intensity) related to the receptor concentration determined biochemically on a subsequent biopsy with a correlation coefficient of +0.65. In a second series of 56 aspirates examined after lysis and cytocentrifugation, the correlation coefficient was +0.73. For 14 patients, the response of the primary tumour to endocrine therapy was assessed objectively by serial clinical and mammographic measurements (Forrest et al., 1986) and was found to relate strongly to the cytochemical staining of the initial aspirate. The potential and limitations of this technique are discussed.
The presence of oestrogen receptors within a breast tumour is now established as an index of both improved prognosis and increased likelihood of response to endocrine therapy (Hawkins, 1985) . The generation of monoclonal antibodies against the human oestrogen receptor (Greene et al., 1980) has permitted the development of commercial kits for both biochemical (ER-EIA) and histochemical (ER-ICA) assays by Abbott Laboratories. The results of the latter technique have been shown to correlate well with those of established biochemical, steroid-binding (DCC) methods on biopsies of solid tumour (King et al., 1985;  McLelland & Coombes, 1985; McCarty et al., 1985; Hawkins et al., 1986) and the technique has recently been extended to the assessment of receptor status in breast cancer cells collected by needle aspiration (McLelland & Coombes, 1985; Flowers et al., 1985; McLelland et al., 1987; Cavailles et al., 1987; Weintraub et al., 1987) . We set out to examine the feasibility of using such a method and to compare the results of the technique with (a) those of our standard DCC assay on solid biopsy, established 15 years ago and (b) response to endocrine therapy in patients with large primary tumours.
Methods and materials

Patients
Aspirates were taken from patients presenting to the departmental clinic for the first time. The patients' ages ranged from 33 to 76 years. Aspirates were obtained by making approximately 10 passes through the tumour using a 21 gauge needle, mainly by two of us (PAL, EDCA). After preparation of smears for diagnostic cytopathology, residual material was used for fixation and cytochemical staining. In one subset of 14 patients with large tumours (>4cm, T2/T3 and one T4), the patient proceeded after aspiration to wedge biopsy for further biochemical and histological investigations prior to initiating endocrine therapy. The response of the primary tumour was monitored objectively by sequential clinical and mammographic measurements (Forrest et al., 1986) . Of these patients, five received the LHRH agonist Zoladex (ICI 118630), five aminoglutethimide, two 4-hydroxyandrostenedione and two tamoxifen. One patient was premenopausal, 12 were postmenopausal and one was male. Response was classed as regression, progression or stasis depending on a statistical evaluation of the changes in tumour size during a 12-week period (see Forrest et al., 1986 (.300,ul) and three 100,ul aliquots were cytospun for 10min at 1,000rpm (89g) onto slides precoated with polylysine (Abbott) in a Cytospin 2 centrifuge. In order to ensure adhesion of the cells to the slides, these were left to air-dry for 2min, prior to fixation and staining with the Abbott ERICA kit as we have described previously . A single quality control slide (Abbott) was stained in each batch of aspirates.
Each slide was assessed independently by two observers (RAH, KS) for (a) the % cells staining, and (b) an average intensity of staining on a scale of 0, 1, 2 or 3 for all the cells in the cytospun area. After correction for any staining in the 'control' section (exposed to non-specific rat serum), a cytochemical staining index (average intensity of staining x % cells staining/I00) was calculated for the 'test' section (exposed to the anti-receptor antibody). Where there was significant disagreement between the observers (11.8% cases), the slides were accepted after rescoring by mutual consent (7.5%) or rejected as 'unassessable' (4.3%). Specimens showing very few cells, very large amounts of nonspecific (control) staining or for which the formal histopathological report was 'benign' or 'inadequate' were also rejected. Specimens from patients on tamoxifen at aspiration were excluded.
In the second series of aspirates, for example, the 56 assessable specimens were derived from a total of 91 patients, exclusions being 3 because of tamoxifen treatment, 15 unassessable and 17 because the formal diagnostic smear was classified as 'acellular', 'benign' or 'lymphoma'.
Biochemical assay of oestrogen receptor activity Solid tumour was obtained by biopsy or mastectomy, within 1-2 weeks of aspiration. This was used for the determination of oestrogen receptor activity by saturation analysis, with separation of free and bound hormone by dextran-coated charcoal (DCC) adsorption as described previously (Hawkins et al., 1981) . Specimens containing _ 5 fmol oestrogen receptor sites mg-1 soluble protein are considered 'receptor-positive'. Figure 1 ), there was a good correlation between cytochemical and biochemical assays. The reasons for the low degree of staining in a few tumours of higher biochemically determined receptor concentration are not fully resolved. Inspection of such specimens shows that the lower values of staining index derive almost entirely from the small percentage of the cells showing staining and not from a low intensity of staining. However, these specimens were not associated with either poorer cellularity or higher blood content than those showing a stronger correlation between cytochemistry and biochemistry. Nevertheless our finding of a correlation coefficient of + 0.73 (n = 56) for the quantitative relationship between staining on aspirates and receptor site concentration in a biopsy agrees well with the equivalent correlations of +0.74 (n=33) and +0.76 (n=35) reported by Flowers et al. (1985) and Cavailles et al. (1987) respectively. These correlations are higher than that of + 0.48 (n = 95) found by McLelland et al. (1987) , but their series included some comparisons between ERICA staining and DCC assays on different tumour deposits. Weintraub and his colleagues (1987) compared ERICA staining in aspirates and frozen sections from the same tumour specimen and also found a correlation coefficient of + 0.72 (n =31); however, there was a lesser correlation (+0.55) between aspirate staining and the concentration of biochemically determined receptor sites. In general, these correlations are of the same order of magnitude as those found by ourselves (r = + 0.87, n = 34, Hawkins et al., 1986) and others, e.g. Andersen et al. (1986) (r= +0.91, n=35), McCarty et al. (1985) (r= +0.79, n=62) and King et al. (1985) (r=+0.76, n=38) when comparing ERICA staining in frozen or paraffin sections with the concentration of biochemically determined receptor sites in the same tumour specimen. In view of the heterogeneity of breast tumours with respect to oestrogen receptor concentration (e.g. Braunsberg et al., 1975; Hawkins et al., 1977; Senbanjo et al., 1986 ), it may not be possible to attain a better correlation between assays on aspirates and those on excision biopsies.
The relationship between ERICA staining and response to endocrine therapy has been determined on only a small series of patients. Nevertheless, in our experience, the primary tumour model used gives a much more precise index of tumour response than do studies of metastatic disease: it allows receptor activity and response of the same tumour mass to be related. 
